《2019年EULAR关于银屑病关节炎药物治疗管理建议》更新内容解读  

An updated interpretation of 2019 EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies

作　　者：李秀[1] 张姬慧[1] 聂英坤[1] LI Xiu;ZHANG Jihui;NIE Yingkun(Department of Rheumatology,the Second Affiliated Hospital of Harbin Medical University,Harbin 150086,P.R.China)

机构地区：[1]哈尔滨医科大学附属第二医院风湿免疫科,哈尔滨150086

出　　处：《中国循证医学杂志》2021年第3期260-265,共6页Chinese Journal of Evidence-based Medicine

基　　金：黑龙江省博士后科研启动基金(编号:LBH-Q15096)。

摘　　要：银屑病关节炎(psoriatic arthritis,PsA)是一种在患有或有银屑病潜在风险的患者中具有异质性表现的疾病。临床表现分为肌肉骨骼和非肌肉骨骼的表现,病情活动的慢性PsA也常伴发心血管、心理和代谢合并症。尽管治疗PsA的改善病情抗风湿药(disease-modifying antirheumatic drugs,DMARDs)数量不断增加,但临床医生在实践中仍需要指南指导临床决策。基于最新的循证研究成果,2019年欧洲抗风湿病联盟(European League Against Rheumatism,EULAR)在PsA药物管理建议2015年更新的基础上进行了进一步更新,并提出了新的推荐意见。本文对该指南更新内容进行解读,以期为临床治疗PsA提供参考。Psoriatic arthritis(PsA) is a disease with heterogeneous manifestations in patients who have manifest or latent psoriasis. It comprises both musculoskeletal and non-musculoskeletal manifestations. Active chronic PsA is often accompanied by cardiovascular, psychological and metabolic complications. Although the quantity of disease-modifying antirheumatic drugs(DMARDs) indicated for PsA has increased, clinicians still require some guidance in decisionmaking. Based on the latest evidence-based research results, the European League Against Rheumatism(EULAR) in 2019 developed the recommendations for the pharmacological management of PsA updated in 2015 with new recommendations. This paper interprets the update contents of the guideline to provide references for the clinical treatment of PsA.

关 键 词：银屑病关节炎 指南 药物治疗 更新 解读 

分 类 号：R758.63[医药卫生—皮肤病学与性病学] R694.3[医药卫生—临床医学]